Stuart Therapeutics is committed to rapidly developing the power and potential of the PolyCol platform technology to deliver transformative, enhanced therapies to address difficult to treat chronic ophthalmic diseases.
For partnering inquiries, or other questions, please contact us below:
EVP, Program Management and Corporate Development
Stuart Therapeutics has recently completed its Phase 2 clinical trial for its first drug candidate, ST-100 for Dry Eye Disease. The company has also completed extensive in vitro and in vivo research to profile the multiple amino acid sequence variants of the PolyCol platform, including their impact on accelerating tissue healing and reduction of inflammation in other important ophthalmic indications.